TTY Biopharm Company Limited

4105

TW0004105002

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
76.6 ^TWD	+0.13%		+0.79%	-4.73%

Mar. 14	TTY Biopharm Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 08	TTY Biopharm Company Limited Announces Change of CFO and Financial Officer	CI

TTY Biopharm Company Limited Appoints Peng,Cheng-Yi as Research and Development Officer, Effective February 01, 2024

January 30, 2024 at 05:09 am EST

TTY Biopharm Company Limited appointed Peng,Cheng-Yi as Research and Development Officer. Name, title, and resume of the new position holder: Peng,Cheng-Yi, vice president; Education: The University of Iowa, PharmD; Experience: Sunny Pharmtech Inc, research and development vice president Intech Biopharm, vice president. Effective date is February 01, 2024.

Latest news about TTY Biopharm Company Limited

TTY Biopharm Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
TTY Biopharm Company Limited Announces Change of CFO and Financial Officer	Mar. 08	CI
TTY Biopharm Company Limited Proposes Cash Dividend for the Year Ended December 31, 2023, Payable on April 26, 2024	Mar. 08	CI
TTY Biopharm Company Limited Appoints Peng,Cheng-Yi as Research and Development Officer, Effective February 01, 2024	Jan. 30	CI
TTY Biopharm Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03	CI
TTY Biopharm Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
TTY Biopharm Company Limited Receives Milestone Payment from German Pharmaceutical Company for Co-Development of Liposome Product-Pegylipo in Europe	23-08-09	CI
TTY Biopharm Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
TTY Biopharm Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
TTY Biopharm Company Limited Proposes Dividend Distribution for the Year Ended December 31, 2022, Payable on May 5, 2023	23-03-14	CI
Aurobindo Pharma Arm Gets US FDA Nod for Amphotericin B Liposome	22-11-18	MT
TTY Biopharm Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-04	CI
TTY Biopharm Company Limited Announces Internal Audit Officer Changes, Effective November 7, 2022	22-11-04	CI
TTY Biopharm Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-05	CI
TTY Biopharm Company Limited Announces Dividend Distribution, Payable on August 15, 2022	22-07-01	CI
TTY Biopharm Company Limited Announces Cash Dividend for the Year 2021	22-05-26	CI
TTY Biopharm Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
TTY Biopharm Company Limited Announces the Resignation of Chou,Te-Yu as Member of Remuneration Committee	22-03-31	CI
TTY Biopharm Company Limited Proposes Cash Dividend for the Year 2021	22-03-09	CI
TTY Biopharm Company Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-08	CI
TTY Biopharm Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-03	CI
TTY Biopharm Company Limited Announces Its Generic Drug - Arsenic Trioxide Has Been Approved by US FDA	21-10-17	CI
TTY Biopharm Company Limited Announces Cash Dividend for the Year 2020, Payable on 19 October 2021	21-08-25	CI
TTY Biopharm Company Limited Announces Directors Appointments	21-08-25	CI
Tty Biopharm Company Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-05	CI

Chart TTY Biopharm Company Limited

Duration

Period

More charts

Company Profile

TTY Biopharm Co Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of pharmaceutical preparations. The Company mainly operates through six business segments including Cancer Drug segment, Healthcare segment, Anti-Infective Drug segment, Domestic Cardiovascular and Gastrointestinal Drug segment, Mainland Medical Drug segment and the Other segment. The main products include oncology medicines, anti-infective medicines and health care medicines. Oncology medicines are mainly anti-cancer and auxiliary drugs. Anti-infective medicines are mainly back-line antimicrobial agents and influenza vaccines. Medical and health care medicines are mainly gastrointestinal health care, bone health care, metabolic health care, infection treatment drugs. The Company distributes its products in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for TTY Biopharm Company Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

76.6 TWD

Average target price

86.5 TWD

Spread / Average Target

+12.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TTY BIOPHARM COMPANY LIMITED	-4.73%	584M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals